Bracebridge Capital LLC Buys 30,645 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Bracebridge Capital LLC raised its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 7.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 459,216 shares of the company’s stock after acquiring an additional 30,645 shares during the period. Aquestive Therapeutics makes up 0.1% of Bracebridge Capital LLC’s investment portfolio, making the stock its 18th largest position. Bracebridge Capital LLC owned about 0.50% of Aquestive Therapeutics worth $1,635,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. State Street Corp raised its holdings in Aquestive Therapeutics by 52.1% in the 3rd quarter. State Street Corp now owns 1,496,739 shares of the company’s stock worth $7,454,000 after purchasing an additional 512,682 shares during the period. Stifel Financial Corp lifted its holdings in shares of Aquestive Therapeutics by 315.4% in the 4th quarter. Stifel Financial Corp now owns 398,561 shares of the company’s stock worth $1,419,000 after acquiring an additional 302,617 shares during the last quarter. Harvey Capital Management Inc. increased its holdings in Aquestive Therapeutics by 1,419.3% during the fourth quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company’s stock valued at $952,000 after buying an additional 249,790 shares during the period. Raymond James Financial Inc. acquired a new stake in Aquestive Therapeutics in the fourth quarter valued at approximately $498,000. Finally, EntryPoint Capital LLC lifted its holdings in shares of Aquestive Therapeutics by 475.7% during the fourth quarter. EntryPoint Capital LLC now owns 135,797 shares of the company’s stock worth $483,000 after purchasing an additional 112,210 shares during the period. 32.45% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on AQST. Alliance Global Partners reaffirmed a “buy” rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Raymond James set a $7.00 price objective on Aquestive Therapeutics in a research note on Friday, March 7th. Lake Street Capital reduced their target price on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a report on Friday, March 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research note on Wednesday, April 2nd. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Aquestive Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $10.67.

Aquestive Therapeutics Stock Performance

AQST opened at $2.58 on Tuesday. Aquestive Therapeutics, Inc. has a twelve month low of $2.20 and a twelve month high of $5.80. The firm’s fifty day moving average is $2.82 and its two-hundred day moving average is $3.66. The firm has a market cap of $255.09 million, a PE ratio of -5.73 and a beta of 2.59.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The firm had revenue of $11.87 million during the quarter, compared to the consensus estimate of $13.11 million. Equities analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.